Fresenius SE SG&A Expenses 2016-2024 | FSNUY
Fresenius SE annual/quarterly sg&a expenses history and growth rate from 2016 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Fresenius SE sg&a expenses for the quarter ending September 30, 2024 were $0.771B, a 6.32% decline year-over-year.
- Fresenius SE sg&a expenses for the twelve months ending September 30, 2024 were $1.626B, a 74.12% decline year-over-year.
- Fresenius SE annual sg&a expenses for 2023 were $3.415B, a 51.94% decline from 2022.
- Fresenius SE annual sg&a expenses for 2022 were $7.105B, a 10.14% increase from 2021.
- Fresenius SE annual sg&a expenses for 2021 were $6.451B, a 4.01% increase from 2020.
Fresenius SE Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$3,415 |
| 2022 |
$7,105 |
| 2021 |
$6,451 |
| 2020 |
$6,203 |
| 2019 |
$6,055 |
| 2018 |
$5,755 |
| 2017 |
$6,261 |
| 2016 |
$4,759 |
| 2015 |
$4,658 |
Fresenius SE Quarterly SG&A Expenses
(Millions of US $) |
| 2024-09-30 |
$771 |
| 2024-06-30 |
$866 |
| 2024-03-31 |
$769 |
| 2023-12-31 |
$-779 |
| 2023-09-30 |
$823 |
| 2023-06-30 |
$1,733 |
| 2023-03-31 |
$1,638 |
| 2022-12-31 |
$2,092 |
| 2022-09-30 |
$1,621 |
| 2022-06-30 |
$1,736 |
| 2022-03-31 |
$1,657 |
| 2021-12-31 |
$1,705 |
| 2021-09-30 |
$1,533 |
| 2021-06-30 |
$1,687 |
| 2021-03-31 |
$1,526 |
| 2020-12-31 |
$1,866 |
| 2020-09-30 |
$1,437 |
| 2020-06-30 |
$1,360 |
| 2020-03-31 |
$1,540 |
| 2019-12-31 |
$1,796 |
| 2019-09-30 |
$1,378 |
| 2019-06-30 |
$1,477 |
| 2019-03-31 |
$1,404 |
| 2018-12-31 |
$1,512 |
| 2018-09-30 |
$1,400 |
| 2018-06-30 |
$1,438 |
| 2018-03-31 |
$1,405 |
| 2017-12-31 |
$1,865 |
| 2017-09-30 |
$1,463 |
| 2017-06-30 |
$1,487 |
| 2017-03-31 |
$1,445 |
| 2016-12-31 |
$1,196 |
| 2016-09-30 |
$1,215 |
| 2016-06-30 |
$1,169 |
| 2016-03-31 |
$1,179 |
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$21.804B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
